Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies

DSpace/Manakin Repository

Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies

Citable link to this page

 

 
Title: Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies
Author: Liu, Xiaochuan; Wang, Aoli; Liang, Xiaofei; Liu, Juanjuan; Zou, Fengming; Chen, Cheng; Zhao, Zheng; Deng, Yuanxin; Wu, Hong; Qi, Ziping; Wang, Beilei; Wang, Li; Liu, Feiyang; Xu, Yunhe; Wang, Wenchao; Fernandes, Stacey M.; Stone, Richard M.; Galinsky, Ilene A.; Brown, Jennifer R.; Loh, Teckpeng; Griffin, James. D.; Zhang, Shanchun; Weisberg, Ellen L.; Zhang, Xin; Liu, Jing; Liu, Qingsong

Note: Order does not necessarily reflect citation order of authors.

Citation: Liu, X., A. Wang, X. Liang, J. Liu, F. Zou, C. Chen, Z. Zhao, et al. 2016. “Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies.” Oncotarget 7 (33): 53515-53525. doi:10.18632/oncotarget.10650. http://dx.doi.org/10.18632/oncotarget.10650.
Full Text & Related Files:
Abstract: PI3Kδ has been found to be over-expressed in B-Cell-related malignancies. Despite the clinical success of the first selective PI3Kδ inhibitor, CAL-101, inhibition of PI3Kδ itself did not show too much cytotoxic efficacy against cancer cells. One possible reason is that PI3Kδ inhibition induced autophagy that protects the cells from death. Since class III PI3K isoform PIK3C3/Vps34 participates in autophagy initiation and progression, we predicted that a PI3Kδ and Vps34 dual inhibitor might improve the anti-proliferative activity observed for PI3Kδ-targeted inhibitors. We discovered a highly potent ATP-competitive PI3Kδ/Vps34 dual inhibitor, PI3KD/V-IN-01, which displayed 10-1500 fold selectivity over other PI3K isoforms and did not inhibit any other kinases in the kinome. In cells, PI3KD/V-IN-01 showed 30-300 fold selectivity between PI3Kδ and other class I PI3K isoforms. PI3KD/V-IN-01 exhibited better anti-proliferative activity against AML, CLL and Burkitt lymphoma cell lines than known selective PI3Kδ and Vps34 inhibitors. Interestingly, we observed FLT3-ITD AML cells are more sensitive to PI3KD/V-IN-01 than the FLT3 wt expressing cells. In AML cell inoculated xenograft mouse model, PI3KD/V-IN-01 exhibited dose-dependent anti-tumor growth efficacies. These results suggest that dual inhibition of PI3Kδ and Vps34 might be a useful approach to improve the PI3Kδ inhibitor's anti-tumor efficacy.
Published Version: doi:10.18632/oncotarget.10650
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288202/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:31731791
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters